Monoclonal anitbodies (mAb) are small biomolecules, with capability to recognize and bind with high specificity to a diverse range of antigens present in environment or on the surface of cancer cells, bacteria, viruses etc. Since the introduction of the technology about 4 decades ago, rapidly growing demand for the production of mAb is observed, as they present enormous potential and applicability for life sciences, diagnostics as well as development of novel biotherapeutics. The market potential of monoclonal antibodies is constantly growing – in 2013, the income from the sale of drugs based on monoclonal antibodies was estimated to reach $ 75 billion, with an expected increase of approx. 15% annually. The major obstacle in the mAbs production process is it`s high cost due to extremely laborious and multi-step procedure. There are several methods that aim to improve certain stages of the existing procedure, but despite involvement of advanced techniques such as cell sorting, still, a break-through technology is looked for.
A new technology was developed that enables detection and in-situ selection of cells producing monoclonal antibodies (i.e. hybridomas) early after fusion. Detection of positive hybridomas, which is performed at single cell resolution, employs functionalized nanomaterials and their unique spectroscopic properties. Moreover an advanced, dedicated optical techniques have been developed accordingly, which enables removal of undesired cells through intentional killing of unwanted hybridomas by the digitally controlled light-induced process.
The technology allows to detect positive hybridomas at the level of individual cells in a short time after B-cells and myeloma cells fusion, which significantly reduce the duration of the entire selection and cloning process. Monoclonal lines can be obtained in a single procedure without the need for the screening and repeated cloning steps. The process of the culture well plate scanning and detection of productive cells is performed automatically, which eliminates tedious, visual inspection and multiple ELISA analyses, which is currently the test of choice. Early detection of productive hybridomas and elimination of unwanted cells eliminates the need for unproductive hybridoma culturing reducing costs and labour. During the whole process, transferring of cell to new culture plates is not required, diminishing the risk of contamination or the loss of productive hybrydoma due to the overgrowth by unproductive cells The major economic advantage of the proposed technology is a significant simplification and enhancement of the hybridoma selection process which shall translate to faster, less laborious and cost effective procedure.
- Pharmaceutical industry
Posted by Centrum Badań EIT+, Posted on 24.05.2016